BWV BLUE WATER VACCINES INC

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

CINCINNATI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced that it has received a letter from the Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq Stock Market, LLC Listing Rule 5250(c)(1) (the "Rule").

The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (SEC). On October 20, 2023, BWB filed its Form 10-Q for the period ended June 30, 2023, and thus is now current on its SEC financial reporting obligations.

About Blue Water Biotech, Inc.

Blue Water Biotech, Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. The Company currently has Entadfi®, an oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Investor and Media Contact Information:

Russo Partners, LLC

Nic Johnson and Harrison Seidner, PhD

Telephone: (212) 845-4242

Email:



EN
01/11/2023

Underlying

BWVBLUE WATER VACCINES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BLUE WATER VACCINES INC

 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Rob...

Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America  CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech Inc), and Realbotix LLC. (“Realbotix”), a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT) (“Realbotix Parent “), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acq...

February 12, 2026 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix Announces Financing Through a $12.9 Million Private Placemen...

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Se...

September 26, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination ...

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independ...

September 26, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix and Ocuvex Therapeutics announce execution of definitive mer...

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the “Merger Agreement”). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We continue to believe that the proposed transaction with Ocuvex, w...

July 16, 2025 1 EN
 PRESS RELEASE
Free
BWV BLUE WATER VACC...

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Nasdaq Listing ...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch